Dr. Lea Baer, MD
Claim this profileStony Brook University Medical Center
Studies Breast Cancer
Studies Cancer
8 reported clinical trials
23 drugs studied
Area of expertise
1Breast Cancer
HER2 positive
ER negative
PR negative
2Cancer
HER2 positive
ER positive
Stage IV
Affiliated Hospitals
Clinical Trials Lea Baer, MD is currently running
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
More about Lea Baer, MD
Clinical Trial Related9 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Lea Baer, MD has experience with
- Paclitaxel
- Cyclophosphamide
- Carboplatin
- Pembrolizumab
- Biospecimen Collection
- Ribociclib
Breakdown of trials Lea Baer, MD has run
Breast Cancer
Cancer
HER2-Positive Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lea Baer, MD specialize in?
Lea Baer, MD focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER negative.
Is Lea Baer, MD currently recruiting for clinical trials?
Yes, Lea Baer, MD is currently recruiting for 5 clinical trials in Stony Brook New York. If you're interested in participating, you should apply.
Are there any treatments that Lea Baer, MD has studied deeply?
Yes, Lea Baer, MD has studied treatments such as Paclitaxel, Cyclophosphamide, Carboplatin.
What is the best way to schedule an appointment with Lea Baer, MD?
Apply for one of the trials that Lea Baer, MD is conducting.
What is the office address of Lea Baer, MD?
The office of Lea Baer, MD is located at: Stony Brook University Medical Center, Stony Brook, New York 11794 United States. This is the address for their practice at the Stony Brook University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.